biib021 clinical trials
Also written CNF2024 and BIIB021.
- studies test it
- 7
- open now
- 0
- in phase 3
- 0
- first study started
- 2006
How each study uses biib021 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
7 studies that test it; most in 2006 (2)
| Year | Studies |
|---|---|
| 2006 | 2 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses biib021 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Once or Twice Daily Administration of BIIB021 to Subjects With Advanced Solid TumorsCompletedPhase 1BiogenNCT00618735Written as BIIB021
- Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule FindingCompletedPhase 2BiogenNCT01004081Written as BIIB021
- An Open-Label, 18FDG-PET Pharmacodynamic Assessment of the Effect of BIIB021 in Subjects With Gastrointestinal Stromal Tumors (GIST)CompletedPhase 2BiogenNCT00618319Written as BIIB021
- Effect of Food and Antacid on BIIB021 With Advanced Solid TumorsCompletedPhase 1BiogenNCT01017198Written as BIIB021 and Food
- CNF2024 (BIIB021) HER2- (QD) HER2+ (BIW w/Herceptin) PK/PD StudyCompletedPhase 1BiogenNCT00412412Written as CNF2024
- Study of Oral CNF2024 (BIIB021) in Advanced Solid TumorsCompletedPhase 1BiogenNCT00345189Written as CNF2024
- Phase 1, Dose-Escalation Study of Oral CNF2024(BIIB021) in CLLTerminatedPhase 1BiogenNCT00344786Written as CNF2024 (BIIB021)
Codes
What other systems call biib021 · ClinicalTrials.gg INT005139
- UNII (FDA) 851B9FQ7Q0BIIB-021Confirmed FDA, Wikidata
- Wikidata Q27075249biib021Confirmed FDA, Wikidata
- NCI Thesaurus C62517Hsp90 Inhibitor BIIB021One source FDA
- DrugBank DB12359One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 851B9FQ7Q0 | BIIB-021 | Confirmed FDA, Wikidata |
| Wikidata | Q27075249 | biib021 | Confirmed FDA, Wikidata |
| NCI Thesaurus | C62517 | Hsp90 Inhibitor BIIB021 | One source FDA |
| DrugBank | DB12359 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.